Oncolytic Virus Therapy Market to grow with a CAGR of 23.10 %
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Oncolytic Virus Therapy Market.
According
to TechSci Research report, “Global Oncolytic Virus Therapy Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Oncolytic Virus Therapy
Market has valued at USD 15.38 billion in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 23.10% through 2028. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to
strengthen their position in the market.
The
presence of unmet medical needs within the field of cancer treatment is a
significant driver of the demand for oncolytic virus therapy. Oncolytic virus
therapy is often considered when patients have advanced or treatment-resistant
cancers that do not respond well to standard treatments, such as chemotherapy
or radiation therapy. This patient population represents a substantial unmet
need. For certain cancer types, especially those with limited treatment
options, oncolytic virus therapy offers a new and innovative approach. Patients
and healthcare providers turn to these therapies when conventional treatments
have been exhausted. Patients who experience cancer recurrence, where the
cancer returns after initial treatment, often face limited options.
Oncolytic
virus therapy may provide an alternative that can be effective against
recurrent tumors. Some cancers develop in anatomically challenging locations
where surgery or other interventions are difficult. It can be considered for
these cases. Pediatric cancers and rare cancers may have limited treatment
options due to their low prevalence. Oncolytic virus therapy can address unmet
needs in these specific patient populations. Older patients and those with
frail health may not be suitable candidates for aggressive treatments like
surgery or high-dose chemotherapy. Oncolytic virus therapy can be considered as
a more tolerable option for these individuals.
In August 2022, Calidi Biotherapeutics, Inc. (Calidi),
a clinical-stage biotechnology company at the forefront of allogeneic
cell-based platforms for advancing oncolytic virus therapies, was delighted to
announce that City of Hope has received approval from the U.S. Food and Drug
Administration (FDA) to proceed with a physician-sponsored phase 1 clinical
trial. This trial will utilize Calidi's licensed oncolytic virotherapy
platform, NSC-CRAd-S-pk7 (known as NeuroNova), a state-of-the-art therapeutic
candidate. NeuroNova comprises tumor-targeting neural stem cells designed to
deliver an oncolytic adenovirus selectively to tumor sites in patients with
recurrent high-grade glioma, falling under Calidi's NNV-2 program. The upcoming
phase 1 physician-sponsored clinical trial is planned as an open-label,
non-randomized, and multicenter study. Its primary focus, once funding is
secured, will be to assess the safety and tolerability of administering
consecutive doses of NeuroNova to adult patients with recurrent, histologically
confirmed high-grade gliomas (classified as WHO grade III or IV).
Immune
response and clearance represent a notable challenge in the global oncolytic
virus therapy market. The interaction between oncolytic viruses and the immune
system can have a significant impact on the safety and efficacy of these
therapies. The human immune system can recognize and respond to oncolytic
viruses, potentially leading to their clearance before they effectively target
and destroy cancer cells. Immune recognition can limit the therapeutic effect. The
host immune system may mount an antiviral immune response against the oncolytic
virus, preventing its replication and spread within the tumor. This immune
reaction can hinder the therapeutic outcome. Pre-existing neutralizing
antibodies in patients can render oncolytic viruses ineffective by blocking
their ability to infect and replicate within tumor cells. Even if oncolytic
viruses initially infect and replicate in tumor cells, the immune system can
eliminate the infected cells, limiting the treatment's effectiveness. The
immunosuppressive microenvironment within tumors can hamper the effectiveness
of oncolytic viruses by inhibiting the host immune response. Tumor cells may
release factors that suppress immune activity, allowing them to evade detection
and destruction.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" Global Oncolytic Virus Therapy Market”
Global Oncolytic Virus Therapy Market is segmented based
on Virus Type, Application, End User, and by region.
Based on the Virus Type, Global Oncolytic Virus
Therapy Market is segmented into Adenovirus,
Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular
Stomatitis Virus (VSV), Others. Based on Region, North America held the largest share in the Global Oncolytic Virus Therapy Market.
North America has a well-developed financial market that provides access to
capital for biotechnology and pharmaceutical companies. Investment and funding
opportunities are readily available, enabling the research and development of
new therapies, including oncolytic virus treatments. Leading academic and
research institutions in North America have made significant contributions to
the field of oncolytic virus therapy. Researchers and scientists in the region
have been pioneers in developing and advancing these therapies. The region's
high incidence of cancer and the demand for more effective cancer treatments
create a substantial market for oncolytic virus therapies. North American
institutions and companies often engage in collaborations and partnerships,
both domestically and internationally, to advance oncolytic virus therapy
research and development. The region's leadership in the global pharmaceutical
and biotechnology industries naturally extends to the field of oncolytic virus
therapy. It has the influence and resources to shape global trends.
Some
of the major companies operating in the Global
Oncolytic Virus Therapy Market include:
- Amgen
Inc.
- Merck
& Co., Inc.
- Oncolytics
Biotech Inc.
- PsiOxus
Therapeutics Ltd.
- Vyriad,
Inc.
- SillaJen
Biotherapeutics
- Cold
Genesys Inc.
- Sorrento
Therapeutics, Inc.
- Takara
Bio Inc.
- Replimune
Group Inc.
- Genelux
Corporation
Download Free Sample Report
Customers
can also request 10% free customization on this report
“Certain areas, particularly in North
America, are projected to exert significant demand for Oncolytic Virus Therapy.
The growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Oncolytic
Virus Therapy Market in the forecast period," said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based Global management
consulting firm.
"Global Oncolytic Virus Therapy Market by Virus Type (Adenovirus, Herpes Simplex Virus
(HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus
(VSV), Others), By Application (Solid Tumors, Hematological Malignancies), by End
User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), By
Region, By Competition Forecast
& Opportunities, 2018-2028F" has
evaluated the future growth potential of Global Oncolytic Virus Therapy
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Oncolytic Virus
Therapy Market.
Contact
Techsci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com